Get the Stockscreener App
1.1705
8.73%
-0.0895
Gri Bio Inc stock is traded at $1.1705, with a volume of 88,328.
It is down -8.73% in the last 24 hours and down -30.72% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$1.26
Open:
$1.27
24h Volume:
88,328
Relative Volume:
0.35
Market Cap:
$2.87M
Revenue:
-
Net Income/Loss:
$-8.26M
P/E Ratio:
-0.0218
EPS:
-53.609
Net Cash Flow:
$-12.17M
1W Performance:
-10.16%
1M Performance:
-30.72%
6M Performance:
-86.34%
1Y Performance:
-86.99%
1-Day Range:
$1.15
$1.2702
1-Week Range:
$1.15
$1.34
52-Week Range:
$1.10
$30.43
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
1.15 | 3.12M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.59 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.82 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
439.17 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
639.32 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
287.00 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
Combining machine learning predictions for GRI Bio Inc.High Accuracy Trade Setup Identification - Newser
Regression analysis insights on GRI Bio Inc. performancePredictive Screener for Daily Trade Watch - Newser
Technical signs of recovery in GRI Bio Inc.Free Investment Strategy With Low Risk - Newser
Tools to assess GRI Bio Inc.’s risk profileEquity Performance Forecast Based on AI Models - Newser
Is a relief rally coming for GRI Bio Inc. holdersAI Model Forecasting Reversal and Breakout Zones - Newser
Why GRI Bio Inc. stock attracts strong analyst attentionIntraday Price Action Forecast Planner - Newser
GRI Bio Inc. stock trend forecastSmart Entry Signals for Active Traders - Newser
Full technical analysis of GRI Bio Inc. stockFree Stable Entry High Return Opportunities - Newser
GRI Bio (GRI) to Release Quarterly Earnings on Tuesday - Defense World
Does GRI Bio Inc. show high probability of reboundMomentum Stocks with Breakout Potential - Newser
Combining price and volume data for GRI Bio Inc.Neural Model for Stock Price Movement - Newser
GRI Bio Reports Promising Early Biomarker Data in Ongoing Study of GRI-0621 for IPF - Managed Healthcare Executive
Strategies to average down on OXLCFree Buy Low Sell High Stock Watch - Newser
Is it time to cut losses on JTAIFree High Return Stock Focus With Safety - Newser
Flat 2023 Medicare Advantage Use Raises Questions About 2025 Cost Pressures - Managed Healthcare Executive
Using R and stats models for GRI Bio Inc. forecastingWeekly Signal Report with Trend Summary - Newser
What are GRI Bio Inc. company’s key revenue driversTriple-digit profit margins - Jammu Links News
How strong is GRI Bio Inc. company’s balance sheetExplosive earnings growth - Jammu Links News
What markets is GRI Bio Inc. expanding into Is CADE stock a good long term investment option - Jammu Links News
Should I hold or sell GRI Bio Inc. stock in 2025Discover high-impact stocks for your portfolio - Jammu Links News
What institutional investors are buying GRI Bio Inc. stockHigh-octane financial growth - Jammu Links News
Does GRI Bio Inc. stock perform well during market downturnsBreakneck growth rates - Jammu Links News
What analysts say about GRI Bio Inc. stockHigh-octane gains - Jammu Links News
What is GRI Bio Inc. company’s growth strategyMaximize gains with professional stock picks - Jammu Links News
Is it the right time to buy GRI Bio Inc. stockUnstoppable trading performance - Jammu Links News
How volatile is GRI Bio Inc. stock compared to the marketAchieve consistent profits with proven strategies - Jammu Links News
What catalysts could drive GRI Bio Inc. stock higher in 2025Unprecedented growth rates - Jammu Links News
What is the dividend policy of GRI Bio Inc. stockLow Risk Forecasts For Smart Trading - Jammu Links News
Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday? - 富途牛牛
GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
GRI Bio Plunges 37.62%—What’s Fueling This Sharp Drop in a Biotech Breakthrough? - AInvest
GRI Bio Inc (GRI) Stock: A Comprehensive 52-Week Review - investchronicle.com
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor 'What This Means” Segment - The Manila Times
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
XPO Reports Q2 2025 Earnings: Adjusted EPS of $1.05, Revenue of $2.08 Billion - AInvest
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment - GlobeNewswire Inc.
GRI Bio Announces Pricing of $5.0 Million Public Offering - ADVFN Brasil
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ('IPF') - ADVFN Brasil
GRI Bio Announces Closing of $5.0 Million Public Offering - ADVFN Brasil
Nasdaq Surges Over 1%; Microsoft Posts Upbeat Earnings - Benzinga
GRI Bio reports positive interim biomarker results in IPF treatment study - Investing.com Nigeria
GRI Bio Announces Positive Interim Data for GRI-0621 - TipRanks
GRI Bio reports positive interim biomarker results in IPF treatment study By Investing.com - Investing.com South Africa
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.51%
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):